SEC Form 4 · accession 0001209191-17-060706

Biohaven Pharmaceutical Holding Co Ltd. · BHVN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).

Reporting owner

James Engelhart

Officer — Chief Financial Officer

Period of report

Nov 9, 2017

Accepted (ET)

Nov 14, 2017 · 5:52 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001689813

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Shares	Nov 9, 2017	M	21,600	$0.61	A	25,176	D
Common Shares^F2	Nov 9, 2017	S	13,083	$26.26	D	12,093	D
Common Shares^F3	Nov 9, 2017	S	8,517	$27.37	D	3,576	D
Common Shares	Nov 10, 2017	M	8,938	$0.61	A	12,514	D
Common Shares^F4	Nov 10, 2017	S	8,938	$26.28	D	3,576	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (Right to Buy)^F5	$0.61	Nov 9, 2017	M	21,600	D	—	Nov 25, 2024	Common Shares	21,600	40,900	D
Employee Stock Option (Right to Buy)^F5	$0.61	Nov 10, 2017	M	8,938	D	—	Nov 25, 2024	Common Shares	8,938	31,962	D

Explanation of responses

F1These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.96 - $26.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.96 - $27.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.74 - $26.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
F5The shares underlying this option vested as to 25% of the shares on November 26, 2014, with the remainder vesting in 3 equal installments on the first, second and third anniversaries of the grant date, subject to the reporting person's continued service as of each applicable vesting date.